Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Core Viewpoint - The article discusses the tragic case of a 19-year-old student who died due to an allergic reaction to Ceftriaxone, highlighting the ongoing issues in the medical field regarding drug administration and patient safety [1][3][18]. Summary by Sections Incident Overview - A 19-year-old student, Xiaotao, died after an allergic reaction to Ceftriaxone during treatment for gastroenteritis, raising concerns about medical staff availability and patient monitoring [1][2]. Medical Response and Controversy - The hospital stated that not performing a skin test before administering Ceftriaxone was appropriate, as there are no regulations mandating it, and medical staff were attending to multiple patients [2][3]. Historical Context of Ceftriaxone Reactions - Xiaotao's case is not isolated; previous incidents have been reported where patients suffered fatal allergic reactions to Ceftriaxone, indicating a pattern of serious adverse effects associated with this antibiotic [5][6]. Adverse Reactions and Complications - Ceftriaxone has been linked to various severe adverse reactions, including anaphylactic shock and neurological disorders, necessitating careful monitoring, especially in patients with renal issues [6][7]. Usage Statistics and Market Insights - The global market for antibiotics reached $45.6 billion in 2023, with over 30% attributed to cephalosporins, highlighting the significant role of these drugs in medical treatment [14]. - In China, cephalosporins account for 41% of all antibiotic usage, with Ceftriaxone being a major contributor to this statistic [14][15]. Regulatory and Safety Concerns - The article emphasizes the need for improved management and monitoring practices in hospitals to prevent similar tragedies, as well as the importance of understanding patient allergy histories before administering cephalosporins [7][12][17]. Recommendations for Practice - Experts suggest that the focus should not solely be on skin testing but rather on comprehensive patient history and careful monitoring during drug administration to mitigate risks associated with cephalosporins [9][10][12].

Core Viewpoint - The recent death of a 19-year-old student in Hubei due to an allergic reaction to Ceftriaxone Sodium has sparked significant public outcry regarding the safety and administration of cephalosporin antibiotics, particularly in the context of medical negligence and patient care standards [1][2][3]. Group 1: Incident Overview - The student, Xiaotao, experienced severe allergic reactions after being administered Ceftriaxone Sodium, leading to her death on April 20, 2023, despite attempts at resuscitation [1]. - The hospital's response indicated that there is no requirement for skin testing before administering Ceftriaxone, and that medical staff are responsible for multiple patients, which raises questions about patient monitoring [1][2]. Group 2: Historical Context - Xiaotao is not the first victim of adverse reactions to cephalosporins; previous cases include a patient in 2018 who died shortly after receiving Ceftriaxone, and an 8-year-old child who also died after being treated with the same drug [3]. - Reports indicate that cephalosporins, particularly Ceftriaxone, have been linked to a high incidence of severe allergic reactions and fatalities, with significant numbers reported in adverse drug reaction monitoring [3][4]. Group 3: Drug Safety and Usage - Ceftriaxone Sodium is considered relatively safe, with an allergic reaction incidence of 3.49 per thousand patients, which is lower than that of penicillin [4]. - However, the drug's long half-life and renal excretion raise concerns for patients with kidney issues, as it can lead to drug accumulation and neurological complications [4][5]. Group 4: Regulatory and Clinical Practices - The National Health Commission has stated that routine skin testing for cephalosporins is not recommended, as it does not effectively predict allergic reactions [6][7]. - The emphasis on skin testing may lead to inappropriate prescribing practices, potentially increasing the risk of antibiotic resistance by shifting to broader-spectrum antibiotics unnecessarily [8][9]. Group 5: Market and Industry Implications - The global market for antibiotics is substantial, with a market size of $45.6 billion in 2023, of which over 30% is attributed to cephalosporins [11]. - In China, cephalosporins account for 41% of all antibiotic usage, highlighting the critical need for proper usage guidelines and monitoring to prevent adverse events [11][12]. Group 6: Future Considerations - The ongoing issues with cephalosporin usage, including off-label and excessive dosing, have raised alarms within the industry, prompting calls for better management and oversight [12]. - The need for improved patient monitoring and adherence to guidelines is essential to prevent tragedies similar to Xiaotao's case from recurring [13].